SinoMab BioScience ROCE
¿Qué es el ROCE de SinoMab BioScience?
El ROCE de SinoMab BioScience Limited es 0.00%
¿Cuál es la definición de ROCE?
El retorno sobre el capital empleado (ROCE) es una relación financiera que mide la rentabilidad de una empresa y la eficiencia con la que se utiliza su capital.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE de compañías en Sector Health Care en HKSE en comparadas con SinoMab BioScience
¿Qué hace SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Empresas con roce similar a SinoMab BioScience
- Omega Alpha Spac tiene ROCE de -0.01%
- The Gap tiene ROCE de -0.01%
- Elemental Royalties Ltd tiene ROCE de -0.01%
- Auburn National Bancorp tiene ROCE de -0.01%
- Galaxy Digital tiene ROCE de -0.01%
- The Gap tiene ROCE de -0.01%
- SinoMab BioScience tiene ROCE de 0.00%
- Tejon Ranch Co tiene ROCE de 0.01%
- Glen Burnie Bancorp tiene ROCE de 0.02%
- MSP Steel & Power tiene ROCE de 0.02%
- TTL Beteiligungs- und Grundbesitz-AG tiene ROCE de 0.03%
- First Foundation Inc tiene ROCE de 0.03%
- FirstMark Horizon Acquisition tiene ROCE de 0.03%